Dengue vaccine candidate: Preclinical testing completed
by Press Release from Outbreak News Today on (#4WBHY)
By NewsDesk @bactiman63 Emergex Vaccines Holding Limited, a biotechnology company developing population-based synthetic disease prophylaxis 'set-point' vaccines in the field of infectious diseases, today announced the successful completion of preclinical testing of its lead vaccine candidate for Dengue Fever. The vaccine construct, which comprises Nature's gene-chip peptides bound to a quantum cluster gold nanoparticle delivery ["]
The post Dengue vaccine candidate: Preclinical testing completed appeared first on Outbreak News Today.